STOCKHOLM – In a standout performance that underscores the resilience and innovation of Nordic pharmaceutical leadership, AstraZeneca PLC reported a 27% year-on-year increase in profit for the second quarter of 2024, fuelled by strong revenue growth across its oncology, cardiovascular, and respiratory portfolios.
The UK-based multinational, which maintains significant R&D operations in Sweden and Denmark, posted a quarterly profit of $1.89 billion (up from $1.49 billion in Q2 2023), with total revenue rising 18% to $13.2 billion. The results exceeded analyst expectations and reflect the company’s strategic focus on high-growth therapeutic areas and expansion in key international markets, particularly the United States and Asia-Pacific.
Strong Pipeline and Market Leadership
AstraZeneca’s success in Q2 was largely driven by continued strong sales of its flagship oncology drugs, including Tagrisso and Enhertu. Tagrisso, used in the treatment of non-small cell lung cancer, generated $1.5 billion in revenue, while Enhertu—a joint development with Japan’s Daiichi Sankyo—posted a remarkable 75% year-on-year growth, reaching $1.3 billion in sales. The drug has gained traction in breast, gastric, and lung cancer treatments, with recent approvals expanding its market potential.
“Our second-quarter performance reflects the strength of our science-led strategy and the growing global demand for innovative medicines,” said Pascal Soriot, Chief Executive Officer of AstraZeneca. “We are not only delivering for patients but also creating sustainable value for shareholders and stakeholders across the Nordic region and beyond.”
Nordic Innovation at the Core
Despite being headquartered in Cambridge, UK, AstraZeneca’s Nordic operations remain pivotal to its innovation engine. The company’s research centre in Mölndal, near Gothenburg, Sweden, is one of its largest R&D hubs, employing over 2,000 scientists and playing a key role in the discovery of new biologics and small-molecule therapies.
In Denmark, AstraZeneca has recently expanded its collaboration with the University of Copenhagen and the Technical University of Denmark (DTU) to accelerate AI-driven drug discovery. These partnerships are part of a broader Nordic strategy to leverage the region’s strong academic institutions and digital infrastructure.
“Sweden and Denmark are global leaders in life sciences innovation,” noted Dr. Lina Bergqvist, Head of R&D at AstraZeneca Nordic. “Our ability to attract top scientific talent and collaborate with world-class universities gives us a competitive edge in developing next-generation therapies.”
Strategic Expansion and Sustainability
Beyond product performance, AstraZeneca continues to invest in sustainable operations. The company reaffirmed its commitment to achieving carbon neutrality across its operations by 2025 and has allocated $500 million toward green manufacturing initiatives in Europe, including upgrades to its Gothenburg and Copenhagen facilities.
In addition, AstraZeneca has launched a new Nordic Health Equity Initiative, aimed at improving access to medicines in underserved communities across the region. The program includes partnerships with public health agencies in Finland, Norway, and Iceland to pilot digital health platforms for early disease detection.
Market Reaction and Outlook
Investors responded positively to the earnings report, with AstraZeneca’s London-listed shares rising 4.2% in early trading. Analysts at Nordea Markets praised the company’s “disciplined execution and robust pipeline,” upgrading their target price to £120.
Looking ahead, AstraZeneca projects full-year revenue growth of 15–17% at constant exchange rates, with further contributions expected from upcoming launches, including the cholesterol-lowering drug Evinacumab and the respiratory candidate AZD0424.
A Nordic Model of Global Success
AstraZeneca’s Q2 results serve as a powerful example of how Nordic values—innovation, sustainability, and collaboration—can drive global competitiveness in the pharmaceutical sector. As the company continues to scale its operations and deliver life-changing treatments, its Nordic roots remain a cornerstone of its enduring success.
For the Nordic Business Journal, this performance not only highlights AstraZeneca’s financial strength but also reinforces the region’s role as a powerhouse of scientific advancement and ethical enterprise in the global economy.